Please login to the form below
reimbursement
This page shows the latest reimbursement news and features for those working in and with pharma, biotech and healthcare.
UK approval for Seagen’s oral HER2 inhibitor Tukysa
We are pleased Tukysa is now authorised in the UK, and we look forward to further collaborating with the national reimbursement bodies to ensure it is available to adult patients,” he
Latest news
-
UK selects Shionogi’s Fetcroja for antimicrobial reimbursement scheme
The antibiotic treats infections caused by aerobic Gram-negative bacteria. Shionogi’s novel antibiotic Fetcroja has been selected for inclusion in a pilot subscription reimbursement scheme, launched by the UK’s ... Shionogi strongly supports the
-
Pierre Fabre’s Braftovi scores NICE backing for BRAF+ colorectal cancer
Securing NHS reimbursement is the culmination of collaborative discussions that we have been having with NICE and NHS England since the end of last year,” said Laura McMullin, general manager UK
-
MSD launches antibiotic combo Recarbrio in UK
Current reimbursement frameworks simply do not support the level of sustained R&D investment that is needed to tackle AMR. ... While the UK’s efforts to pilot a new subscription model of antibiotic reimbursement is a step in the right direction, its
-
EU announces agreement with Gilead for remdesivir supply
Both deals temporarily remove the need for country-by-country reimbursement processes in recognition of the current health crisis.
-
Launch leaders’ blog part 1
Here are ten immediate areas to review for your launch:. Are your clinical trial, submission, approval and reimbursement timing assumptions still valid?
More from news
Approximately 40 fully matching, plus 512 partially matching documents found.
Latest Intelligence
-
Assessing the impact of disease prevalence on access and pricing of rare disease drugs in England
The study focused on answering three key questions:. 1. Is disease rarity a predictor of reimbursement? ... Disease rarity is thus not a major driver of reimbursement decisions in value assessments for ODs.
-
Rare genetic diseases – what’s in store for 2021?
Looking beyond purely digital changes, in a lot of countries, healthcare systems have had to rethink how they approach drug approvals and innovate their reimbursement pathways to allow faster access to
-
Transforming clinical trial data into a long-term asset
Throughout the product life cycle, good practice in archiving can prove to be of value when dealing with pharmacovigilance, value-based pricing and reimbursement, as well as in the search for
-
The search for effective drug treatments for COVID-19
The single government price in the developed world aimed to remove the need for lengthy reimbursement processes in each country which resulted to almost simultaneous access for patients around the world.
-
Successful product commercialisation: what can we learn from the rare disease setting?
Holistic services can add value in multiple ways, including support with access and reimbursement, nursing services (eg, supporting drug administration and adverse event management), 24/7 helplines and through patient education. ... Establishing early
More from intelligence
Approximately 12 fully matching, plus 163 partially matching documents found.
Latest appointments
-
New faces at Prime Global, Swordfish Advertising and Wilmington Healthcare
In that role, she provided strategic insight on NHS policies, commissioning and reimbursement pathways.
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team
There he oversaw the oncology-focused company's launch in the region, as well as the launch and UK reimbursement of its PARP inhibitor in recurrent ovarian cancer. ... During her 16-year stint with Amgen, Hamill worked in a number of executive roles,
-
Weekly industry appointments
Brian Jamieson, chairman, Mesoblast, said: “Swedish’s strong understanding of US healthcare resource allocation and reimbursement metrics is in line with the board’s objective to strengthen its commercial focus.”.
-
Claes Buxfeldt joins NDA
He becomes its new HTA director. AstraZeneca’s former global price and reimbursement director Claes Buxfeldt has joined the NDA advisory board.
-
Mereo BioPharma appoints head of patient access and commercial planning
In this role, Hughes-Wilson was responsible for Sobi’s commercialisation approach and led pricing, reimbursement and access teams for the group’s rare disease product portfolio.
More from appointments
Approximately 0 fully matching, plus 21 partially matching documents found.
Latest from PMHub
-
Peadar Coyle announced as Business Development Director for Ashfield Ireland
We see a number of challenges in the Irish market from restructures in mainstream pharma to delays in reimbursement of new medicines.
-
Fishawack Health unveils an unrivaled global market access and HEOR offering with the acquisition of PRMA Consulting
We’re delighted to add a team of market access and health economics strategists with deep specialism in HEOR, healthcare technology assessments, pricing, and reimbursement processes.”.
-
Why you must understand the pricing of patient recruitment companies
This model of reimbursement encourages companies to focus on the number of patients, rather than the quality of patients. ... To improve the diversity of recruitment in clinical trials, the reimbursement model for patient recruitment services needs to be
-
Rare Disease Day – why it’s important to show your stripes
reimbursement pathway.
-
Delphi Technique Virtual Co-creation: A Customer Story
reimbursement and other pain points during the patient journey.
More from PMHub
Approximately 5 fully matching, plus 77 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Medical Writer, Senior Medical Writer, Principal Medical Writer,...
-
Highly Competitive Salary, Bonus &Benefits
- Freelance Account Manager - Creative Healthcare Comms - Immediat...
-
Excellent Day Rate
- Freelance Medical Writer - Creative Healthcare Comms - 2 month t...
-
Excellent Day Rate
-
Account Management
-
Competitive Salary Offered
- Senior Leadership Role – Medical Communications – North West
-
Highly Competitive Salary, Bonus &Benefits
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Content Editor - Biotechnology
-
Salary TBC
- Senior Account Director & Associate Director - Healthcare Ad...
-
Highly Competitive Salary, Bonus &Benefits
- Client Services Director – London or Home Based – Medical Commun...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account / Programme Manager - MedComms - Buckinghamshire
-
Highly Competitive Remuneration packages
- FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...
-
Highly Competitive Day Rate, Bonus &Benefits
- Editor & Senior Editor - Medical Communications - Home Based
-
Highly Competitive Salary, Bonus &Benefits
- AZ showcases data for next-generation PARP inhibitor AZD5305
- Sanofi pays $160m upfront to acquire Tidal Therapeutics
- GSK discontinues two feladilimab trials in head and neck cancer
- Novavax seeks FDA emergency approval for COVID-19 vaccine by May
- Pfizer/BioNTech say their COVID-19 vaccine can be stored at warmer temperatures
- FDA approves new self-injection administration for Xolair
- Lilly asks to revoke emergency authorisation for bamlanivimab monotherapy in the US
- CureVac outlines COVID-19 vaccine production plans ahead of regulatory approval
- Alexion and NICE agree confidential discount for Ultomiris use on the NHS
- Novartis’ MS therapy Kesimpta reduces risk of disability progression regardless of relapses
- Merck & Co halts development of potential COVID-19 drug MK-7110
- Virtually, the same: Is it time to rethink congress strategy?
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- InSite Events™ National Pharma Meeting: A Customer Story
- How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
- Fear or encouragement, which is best to drive behaviour change?
- The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
- The unheard, unseen, and uncorrected effects of COVID-19
- The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...
Quick links
Infographics
